S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Mullen Automotive Stock, The Tide Has Turned
Profit From the Commercial Solar Boom? (Ad)
Is C3.ai Artificial Intelligence Product Suite a Gamechanger?
What do Mastercard Earnings Indicate About Consumer Spending?
A gold storm is coming… (Ad)
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
How to Find Penny Stocks to Invest and Trade
"We need batteries. Literally everywhere." (Ad)
ONSemi Is Marching Higher On Great Results
What Tyson Foods Q1 Means For Staples Stocks
S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Mullen Automotive Stock, The Tide Has Turned
Profit From the Commercial Solar Boom? (Ad)
Is C3.ai Artificial Intelligence Product Suite a Gamechanger?
What do Mastercard Earnings Indicate About Consumer Spending?
A gold storm is coming… (Ad)
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
How to Find Penny Stocks to Invest and Trade
"We need batteries. Literally everywhere." (Ad)
ONSemi Is Marching Higher On Great Results
What Tyson Foods Q1 Means For Staples Stocks
S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Mullen Automotive Stock, The Tide Has Turned
Profit From the Commercial Solar Boom? (Ad)
Is C3.ai Artificial Intelligence Product Suite a Gamechanger?
What do Mastercard Earnings Indicate About Consumer Spending?
A gold storm is coming… (Ad)
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
How to Find Penny Stocks to Invest and Trade
"We need batteries. Literally everywhere." (Ad)
ONSemi Is Marching Higher On Great Results
What Tyson Foods Q1 Means For Staples Stocks
S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Mullen Automotive Stock, The Tide Has Turned
Profit From the Commercial Solar Boom? (Ad)
Is C3.ai Artificial Intelligence Product Suite a Gamechanger?
What do Mastercard Earnings Indicate About Consumer Spending?
A gold storm is coming… (Ad)
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
How to Find Penny Stocks to Invest and Trade
"We need batteries. Literally everywhere." (Ad)
ONSemi Is Marching Higher On Great Results
What Tyson Foods Q1 Means For Staples Stocks
NASDAQ:SRPT

Sarepta Therapeutics - SRPT Stock Forecast, Price & News

$117.84
-1.16 (-0.97%)
(As of 02/6/2023 12:00 AM ET)
Add
Compare
Today's Range
$117.67
$121.11
50-Day Range
$117.10
$132.13
52-Week Range
$61.28
$134.08
Volume
748,434 shs
Average Volume
1.01 million shs
Market Capitalization
$10.34 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$150.14

Sarepta Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
27.4% Upside
$150.14 Price Target
Short Interest
Healthy
7.03% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.65
Upright™ Environmental Score
News Sentiment
0.14mentions of Sarepta Therapeutics in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$94,311 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($8.07) to ($3.93) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.65 out of 5 stars

Medical Sector

72nd out of 1,027 stocks

Pharmaceutical Preparations Industry

25th out of 500 stocks

SRPT stock logo

About Sarepta Therapeutics (NASDAQ:SRPT) Stock

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRPT Stock News Headlines

Profit From the Commercial Solar Boom?
Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
7 Biotech Stocks That Will Make You Rich in 10 Years
SRPT.MW - | Stock Price & Latest News | Reuters
Profit From the Commercial Solar Boom?
Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
9 Analysts Have This to Say About Sarepta Therapeutics
Needham Keeps Their Buy Rating on Sarepta Therapeutics (SRPT)
RBC Capital Keeps Their Buy Rating on Sarepta Therapeutics (SRPT)
Robert W. Baird Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)
Sarepta’s Gene Therapy Set for Quick FDA Review
See More Headlines
Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRPT Company Calendar

Last Earnings
11/03/2021
Today
2/07/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRPT
Previous Symbol
NASDAQ:AVII
Employees
840
Year Founded
1980

Price Target and Rating

Average Stock Price Forecast
$150.14
High Stock Price Forecast
$190.00
Low Stock Price Forecast
$114.00
Forecasted Upside/Downside
+27.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$-418,780,000.00
Pretax Margin
-81.11%

Debt

Sales & Book Value

Annual Sales
$701.89 million
Book Value
$10.66 per share

Miscellaneous

Free Float
82,165,000
Market Cap
$10.34 billion
Optionable
Optionable
Beta
0.98

Social Links


Key Executives

  • Douglas S. IngramDouglas S. Ingram
    President, Chief Executive Officer & Director
  • Ian M. Estepan
    Executive VP, Chief Financial & Accounting Officer
  • Louise Rodino-KlapacLouise Rodino-Klapac
    Chief Scientific Officer & Executive VP
  • Bilal Arif
    Chief Technical Operations Officer
  • Dallan Murray
    Chief Customer Officer & Senior Vice President













SRPT Stock - Frequently Asked Questions

Should I buy or sell Sarepta Therapeutics stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SRPT shares.
View SRPT analyst ratings
or view top-rated stocks.

What is Sarepta Therapeutics' stock price forecast for 2023?

9 Wall Street analysts have issued 12 month price targets for Sarepta Therapeutics' shares. Their SRPT share price forecasts range from $114.00 to $190.00. On average, they predict the company's stock price to reach $150.14 in the next twelve months. This suggests a possible upside of 27.2% from the stock's current price.
View analysts price targets for SRPT
or view top-rated stocks among Wall Street analysts.

How have SRPT shares performed in 2023?

Sarepta Therapeutics' stock was trading at $129.58 at the beginning of 2023. Since then, SRPT shares have decreased by 8.9% and is now trading at $118.04.
View the best growth stocks for 2023 here
.

When is Sarepta Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our SRPT earnings forecast
.

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) issued its quarterly earnings data on Wednesday, November, 3rd. The biotechnology company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($1.86) by $1.26. The biotechnology company had revenue of $189.41 million for the quarter, compared to analysts' expectations of $170.13 million. Sarepta Therapeutics had a negative net margin of 81.76% and a negative trailing twelve-month return on equity of 97.37%. During the same period last year, the company posted ($2.50) EPS.

What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO?

15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sarepta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS).

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

Who are Sarepta Therapeutics' major shareholders?

Sarepta Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.83%), Allspring Global Investments Holdings LLC (0.43%), National Bank of Canada FI (0.34%), Mizuho Markets Americas LLC (0.22%), Wolverine Asset Management LLC (0.00%) and Pinnacle Associates Ltd. (0.11%). Insiders that own company stock include David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, Louise Rodino-Klapac, M Kathleen Behrens, Michael Andrew Chambers, Richard Barry and Stephen Mayo.
View institutional ownership trends
.

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sarepta Therapeutics' stock price today?

One share of SRPT stock can currently be purchased for approximately $118.04.

How much money does Sarepta Therapeutics make?

Sarepta Therapeutics (NASDAQ:SRPT) has a market capitalization of $10.36 billion and generates $701.89 million in revenue each year. The biotechnology company earns $-418,780,000.00 in net income (profit) each year or ($8.21) on an earnings per share basis.

How many employees does Sarepta Therapeutics have?

The company employs 840 workers across the globe.

Does Sarepta Therapeutics have any subsidiaries?
The following companies are subsidiares of Sarepta Therapeutics: Eisai, Myonexus Therapeutics, ST International Holdings Two Inc., Sarepta Securities Corp., and Sarepta Therapeutics Three LLC.
Read More
How can I contact Sarepta Therapeutics?

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The official website for the company is www.sareptatherapeutics.com. The biotechnology company can be reached via phone at (617) 274-4000, via email at investors@sarepta.com, or via fax at 425-354-5038.

This page (NASDAQ:SRPT) was last updated on 2/7/2023 by MarketBeat.com Staff